Idioma: Inglés
Publicado por LAP Lambert Academic Publishing, 2012
ISBN 10: 3848484293 ISBN 13: 9783848484294
Librería: preigu, Osnabrück, Alemania
EUR 43,30
Cantidad disponible: 5 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. Biosimilars | Biosimilar Drug Development | Sunil Kumar Dubey (u. a.) | Taschenbuch | Englisch | LAP Lambert Academic Publishing | EAN 9783848484294 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.
Idioma: Inglés
Publicado por LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3848484293 ISBN 13: 9783848484294
Librería: Mispah books, Redhill, SURRE, Reino Unido
EUR 120,32
Cantidad disponible: 1 disponibles
Añadir al carritoPaperback. Condición: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.
Idioma: Inglés
Publicado por LAP LAMBERT Academic Publishing, 2012
ISBN 10: 3848484293 ISBN 13: 9783848484294
Librería: moluna, Greven, Alemania
EUR 41,67
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Dubey Sunil KumarAt present, I am working as a lecturer in the Department of Pharmacy, Birla Institute of Science & Technology, Pilani. I have published more than 22 research papers of national and international repute and presented.
Idioma: Inglés
Publicado por LAP Lambert Academic Publishing, 2012
ISBN 10: 3848484293 ISBN 13: 9783848484294
Librería: AHA-BUCH GmbH, Einbeck, Alemania
EUR 49,59
Cantidad disponible: 2 disponibles
Añadir al carritoTaschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - This review gives clear insight on Biosimilars. Biosimilars the follow-on biologicals is the new area for a pharmaceutical industry to consider whether it suits its expertise, its business interest and offers for it opportunities for growth. This review explores Biosimilar Drug Development from the view-point of a biopharmaceutical company and proposes key points that a company needs to consider through the process of planning biosimilar drug development. It examines significant developments in the biosimilars market and will arm the reader with scientific, regulatory and strategic information needed to face new opportunities as well as the challenges of the biosimilars revolution.